Raymond James & Associates Sells 650 Shares of Atrion Co. (NASDAQ:ATRI)

Raymond James & Associates lessened its holdings in shares of Atrion Co. (NASDAQ:ATRI) by 9.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,383 shares of the medical instruments supplier’s stock after selling 650 shares during the quarter. Raymond James & Associates’ holdings in Atrion were worth $2,418,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. First Financial Corp IN purchased a new position in shares of Atrion during the 4th quarter valued at about $136,000. SG Americas Securities LLC purchased a new position in shares of Atrion during the 4th quarter valued at about $108,000. Deutsche Bank AG raised its holdings in shares of Atrion by 10.2% during the 3rd quarter. Deutsche Bank AG now owns 810 shares of the medical instruments supplier’s stock valued at $335,000 after buying an additional 75 shares in the last quarter. Comerica Bank purchased a new position in shares of Atrion during the 3rd quarter valued at about $178,000. Finally, Creative Planning raised its holdings in shares of Atrion by 2.1% during the 3rd quarter. Creative Planning now owns 3,888 shares of the medical instruments supplier’s stock valued at $1,606,000 after buying an additional 81 shares in the last quarter. Institutional investors own 66.19% of the company’s stock.

Atrion Stock Performance

Shares of ATRI stock opened at $398.68 on Tuesday. The company has a market capitalization of $701.68 million, a P/E ratio of 36.15 and a beta of 0.60. Atrion Co. has a fifty-two week low of $274.98 and a fifty-two week high of $670.00. The stock has a 50 day moving average price of $398.46 and a two-hundred day moving average price of $364.89.

Atrion (NASDAQ:ATRI) last issued its earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 EPS for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The company had revenue of $43.58 million for the quarter.

Atrion Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were paid a $2.20 dividend. This represents a $8.80 annualized dividend and a dividend yield of 2.21%. The ex-dividend date of this dividend was Thursday, March 14th. Atrion’s payout ratio is 79.78%.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Atrion from a “sell” rating to a “hold” rating in a report on Friday, March 1st.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.